Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications
Results of the first phase 3 trial in this field were announced.
Okogen Secures Ora to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
Okogen, Inc. to present at 2017 Biotech Showcase
Ophthalmic Product Development Insights
How this particular type of gene editing works and a discussion of its potential uses in the future.
Second Disease Indication Shows Versatility of Paracrine Signaling Solution
Like death and taxes, presbyopia is one of life’s certainties, an inevitable companion to the aging process
A look at ocular/nasal interactions and how they can affect our
Early detection may allow treatment, and possibly reversal. Part 2 of a two-part series.